Abstract：
UNASSIGNED: Functional constipation (FC) is a common childhood condition, diagnosed via the Rome IV criteria. Standard therapy includes lifestyle and dietary modification followed by initiation of osmotic laxative therapy. About 30% of children continue to experience symptoms related to FC despite appropriate management. New pharmacologic, surgical, and neuromodulatory therapies for FC are now available for use in adult and pediatric populations. In 2023, the first pharmacologic agent, linaclotide, obtained FDA approval for treatment of FC in children 6-17 years old.
UNASSIGNED: This article reviews current and emerging pharmacologic, surgical, and neuromodulation therapies for the management of FC in pediatric patients. Efficacy and safety data regarding each of these modalities was reviewed and discussed.
UNASSIGNED: Advancements in therapeutics available for the management of FC necessitate further investigation on safety and efficacy in pediatric populations. Careful consideration should be taken in choosing an available treatment with limited pediatric evidence as adult and pediatric FC have different underlying pathophysiology and require a different therapeutic approach. Standardization of methodology and pediatric endpoints are needed to optimize ability to compare efficacy of different treatments. We predict the future of pediatric FC management will include a personalized approach to care, resulting in improved outcomes.
UNASSIGNED: This article reviews current and emerging pharmacologic, surgical, and neuromodulation therapies for the management of FC in pediatric patients. Efficacy and safety data regarding each of these modalities was reviewed and discussed.
UNASSIGNED: Advancements in therapeutics available for the management of FC necessitate further investigation on safety and efficacy in pediatric populations. Careful consideration should be taken in choosing an available treatment with limited pediatric evidence as adult and pediatric FC have different underlying pathophysiology and require a different therapeutic approach. Standardization of methodology and pediatric endpoints are needed to optimize ability to compare efficacy of different treatments. We predict the future of pediatric FC management will include a personalized approach to care, resulting in improved outcomes.
摘要：
■功能性便秘（FC）是一种常见的儿童疾病，通过罗马IV标准诊断。标准治疗包括生活方式和饮食调整，然后开始渗透泻药治疗。尽管进行了适当的管理，但仍有约30％的儿童继续出现与FC相关的症状。新的药理学，外科,和FC的神经调节疗法现在可用于成人和儿科人群。2023年，第一种药物，利那洛肽,获得FDA批准用于治疗6-17岁儿童的FC。
■本文回顾了当前和新兴的药理学，手术和神经调节疗法用于儿科患者FC的管理。回顾并讨论了每种模式的疗效和安全性数据。
■可用于FC管理的治疗方法的进步需要进一步研究儿科人群的安全性和有效性。由于成人和小儿FC具有不同的潜在病理生理学并且需要不同的治疗方法，因此在选择儿科证据有限的可用治疗方法时应仔细考虑。需要方法学和儿科终点的标准化以优化比较不同治疗的功效的能力。我们预测儿科FC管理的未来将包括个性化的护理方法，从而改善结果。
■本文回顾了当前和新兴的药理学，手术和神经调节疗法用于儿科患者FC的管理。回顾并讨论了每种模式的疗效和安全性数据。
■可用于FC管理的治疗方法的进步需要进一步研究儿科人群的安全性和有效性。由于成人和小儿FC具有不同的潜在病理生理学并且需要不同的治疗方法，因此在选择儿科证据有限的可用治疗方法时应仔细考虑。需要方法学和儿科终点的标准化以优化比较不同治疗的功效的能力。我们预测儿科FC管理的未来将包括个性化的护理方法，从而改善结果。
